IPP Bureau
Regeneron and Telix strike major radiopharma pact in push into next-gen cancer therapies
By IPP Bureau - April 15, 2026
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
FDA presses 2,200+ companies to fix missing clinical trial results
By IPP Bureau - April 15, 2026
Move amid evidence of widespread reporting gaps
Pinky Promise opens first physical clinic in Mumbai, expands women’s hybrid healthcare model
By IPP Bureau - April 15, 2026
AI-enabled women’s digital clinic brings in-person consultations to complement app-led care after serving over 400,000 women across India
Aragen launches ChemiSHE, India’s first women-led chemistry synthesis lab
By IPP Bureau - April 14, 2026
CRDMO plans to add 800–1,000 women across scientific and leadership roles over three years
Alexion to showcase broad neurology pipeline at AAN 2026 with 20 presentations
By IPP Bureau - April 14, 2026
The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
New guidance aims to speed up diagnosis of childhood abdominal cancers
By IPP Bureau - April 14, 2026
Backed by funding from an NIHR Doctoral Award, the guidance is focused on spotting abdominal tumours
AKM and Kyoto University break ground with 2 µm PCSEL laser
By IPP Bureau - April 14, 2026
Paves the way for next-gen ultra-precise gas sensing
Imagene AI teams up with Daiichi Sankyo to supercharge cancer drug development
By IPP Bureau - April 14, 2026
A major push to sharpen the future of cancer treatment is underway
Kolkata gets advanced liver care hub as Manipal Hospitals targets critical treatment gap
By IPP Bureau - April 14, 2026
The launch saw the presence of senior clinicians and leadership from the Manipal Hospitals network
WHO unites 800+ institutions in historic global health push to prepare for next pandemic threat
By IPP Bureau - April 14, 2026
Scientists at the forum warned of an increasingly volatile health landscape
Boehringer Ingelheim & BioNTech launch high-stakes lung cancer combo trial
By IPP Bureau - April 14, 2026
BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
Thermo Fisher and Singapore’s PRECISE launch major proteomics push in 100,000-person study
By IPP Bureau - April 14, 2026
The study’s multi-technology design is intended to improve reproducibility, strengthen regulatory-grade evidence generation
GoodRx partners with Eli Lilly to expand access to new oral GLP-1 Foundayo & Zepbound KwikPen
By IPP Bureau - April 14, 2026
GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access
Kauvery Hospital conducts 4th edition of ECG Masterclass 2026; 400+ medical professionals attend
By IPP Bureau - April 14, 2026
Workshop on ECG interpretation also marks launch of “Handbook on ECGs – Volume 2”
